NCT05383183View on ClinicalTrials.gov

Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 9, 2025

Conditions
Alzheimer Disease
Interventions
DRUG

Choline Alfoscerate 400mg

Oral administration

DRUG

Placebo

Oral administration

Trial Locations (4)

Unknown

RECRUITING

Changwon Fatima Hospital, Changwon

RECRUITING

Gachon University Gil Medical Center, Incheon

RECRUITING

CHA Bundang Medical Center, Seongnam

NOT_YET_RECRUITING

The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul

All Listed Sponsors
lead

Daewoong Bio Inc.

INDUSTRY